Fennec Pharmaceuticals Announces Proposed Offering of Common Shares

Core Viewpoint - Fennec Pharmaceuticals Inc. is initiating an underwritten public offering of its common shares, with plans to use the proceeds for debt repayment and general corporate purposes [1][2]. Group 1: Offering Details - The company intends to offer common shares and grant underwriters a 30-day option to purchase an additional 15% of the shares sold in the offering [1]. - The offering is being conducted under a registration statement that has been declared effective by the SEC, with a preliminary prospectus supplement to be filed [3]. Group 2: Use of Proceeds - Net proceeds from the offering will be used to repurchase certain indebtedness, with any remaining funds allocated for working capital and general corporate purposes [2]. Group 3: Company Background - Fennec Pharmaceuticals focuses on combating ototoxicity in cancer patients undergoing cisplatin-based chemotherapy, primarily through its product PEDMARK, which has received various regulatory approvals [5][6]. - PEDMARK has Orphan Drug Exclusivity in the U.S. and PEDMARQSI has received Pediatric Use Marketing Authorization in Europe, providing significant market protection [7].